These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9380591)

  • 21. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
    Potters L; Calugaru E; Jassal A; Presser J
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Cancer J; 2001; 7(5):404-12. PubMed ID: 11693899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
    Lee HK; Adams MT; Motta J
    Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
    Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
    Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated.
    Talcott JA; Clark JA; Stark PC; Mitchell SP
    J Urol; 2001 Aug; 166(2):494-9. PubMed ID: 11458054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.
    Teloken PE; Ohebshalom M; Mohideen N; Mulhall JP
    J Urol; 2007 Dec; 178(6):2521-5. PubMed ID: 17937948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose brachytherapy for treating prostate cancer: nursing considerations.
    Colella J; Scrofine S
    Urol Nurs; 2004 Feb; 24(1):39-44, 52. PubMed ID: 15054909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer of the prostate: treatment and nursing implications.
    Held JL; Osborne DM; Volpe H; Waldman AR
    Oncol Nurs Forum; 1994 Oct; 21(9):1517-29. PubMed ID: 7816678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors affecting patient selection for prostate brachytherapy: what nurses should know.
    Zeroski D; Abel L; Butler WM; Wallner K; Merrick GS
    Clin J Oncol Nurs; 2005 Oct; 9(5):553-60. PubMed ID: 16235582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration.
    Nag S; Scaperoth DD; Badalament R; Hall SA; Burgers J
    Urology; 1995 Jan; 45(1):87-92. PubMed ID: 7817484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiation safety parameters following prostate brachytherapy.
    Smathers S; Wallner K; Korssjoen T; Bergsagel C; Hudson RH; Sutlief S; Blasko J
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):397-9. PubMed ID: 10487562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Teaching program for patients receiving interstitial radioactive iodine 125 for cancer of the prostate.
    Champagne EE; Kane NE
    Oncol Nurs Forum; 1980; 7(1):12-5. PubMed ID: 6898059
    [No Abstract]   [Full Text] [Related]  

  • 35. Ultrasonically guided interstitial brachytherapy for prostate cancer: care of the patient in ambulatory surgery.
    Redmond MC
    J Perianesth Nurs; 1998 Jun; 13(3):156-64; quiz 164-7. PubMed ID: 9801541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brachytherapy: a minimally invasive option for treating prostate cancer.
    Stahlinski CR; Friedman FP; Finklestein S
    Minim Invasive Surg Nurs; 1994; 8(3):106-9. PubMed ID: 7812389
    [No Abstract]   [Full Text] [Related]  

  • 37. Understanding stereotactic radiosurgery for intracranial tumors, seed implants for prostate cancer, and intravascular brachytherapy for cardiac restenosis.
    Witt ME; Haas M; Marrinan MA; Brown CN
    Cancer Nurs; 2003 Dec; 26(6):494-502. PubMed ID: 15022981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term potency preservation following brachytherapy for prostate cancer.
    Roach M
    BJU Int; 2012 Jul; 110(2):225. PubMed ID: 22734476
    [No Abstract]   [Full Text] [Related]  

  • 39. The more things change, the more they stay the same--or do they?
    Katz A
    Oncol Nurs Forum; 2013 Jan; 40(1):12-3. PubMed ID: 23269762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transperineal I-125 implant of the prostate: an accurate and less morbid procedure.
    Kumar PP; Bartone FF; Taylor JE; Pelton J; Jones EO
    Nebr Med J; 1982 Jul; 67(7):174-7. PubMed ID: 7121625
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.